| Literature DB >> 26134386 |
Mats Salemyr1, Olle Muren1, Torbjörn Ahl1, Henrik Bodén1, Thomas Eisler1, André Stark1, Olof Sköldenberg1.
Abstract
BACKGROUND ANDEntities:
Mesh:
Year: 2015 PMID: 26134386 PMCID: PMC4750763 DOI: 10.3109/17453674.2015.1067087
Source DB: PubMed Journal: Acta Orthop ISSN: 1745-3674 Impact factor: 3.717
Stem characteristics
| Stem properties | Ultra-short stem | Conventional stem |
| Design | Anatomically wedge-shaped | Straight tapered (3°) |
| Material | Titanium alloy (Ti-6Al-4V) | Titanium alloy (Ti-6Al-4V) |
| Coating | Fully porous-coated with sintered beads, mean pore size 250 µm, covered with 30 µm highly amorphous hydroxyapatite (Duofix) | Proximal 30% porous-coated, pore size of 100–200 µm covered with plasma-sprayed hydroxy-apatite (thickness 40–70 µm, crystallinity 50–70%, purity >95%) |
| Distal tip textured | Distal 70% textured | |
| Stem lengths used | 71–83 mm | 130–155 mm |
Figure 1.The ultra-short stem.
Figure 2.Gruen zones measured from the DXA scanner. Zones 1–2 and 6–7 in the ultra-short stem group were compared to zones 1 and 7, respectively, in the conventional stem group.
Figure 3.Study protocol. DXAf: DXA scan of proximal femur (WHO total hip); DXAv: DXA scan of vertebrae L1–L4 (WHO lumbar spine); DXAg: DXA scan of Gruen zones; RSA: radiostereometry radiographs; Rad: anterioposterior and lateral conventional radiographs; Clin: clinical outcome scores including Harris hip score (HHS), WOMAC, and EQ-5D.
Precision of DXA measurements expressed as coefficients of variation in percent (CV%)
| Gruen zone | 1 a | 2 b | 3 | 4 | 5 | 6 b | 7 a |
| CV% | 5.5 | 3.3 | 4.7 | 2.8 | 4.1 | 2.7 | 7.0 |
For the ultra-short stem, Gruen zone 1 and 2 were analyzed together as zone 1, and zone 6 and 7 were analyzed as zone 7.
Only the precision for the conventional stem is shown.
Figure 4.Consort flow chart.
Baseline characteristics of the study participants
| Baseline characteristics | Ultra-short stem (n = 26) | Conventional stem (n = 25) |
| Age, years a | 62 (5) | 62 (6) |
| Male / female, n | 11 / 15 | 11 / 14 |
| Weight, kg a | 79 (15) | 82 (13) |
| Height, cm a | 171 (10) | 172 (8) |
| BMI a | 27 (4) | 28 (4) |
| Charnley class, n (A / B / C) | 16 / 10 / 0 | 18 / 7 / 0 |
| ASA class, n (1–2 / 3–4) | 21 / 5 | 20 / 5 |
| Harris hip score, preop.b | 56 (29–68) | 46 (10–70) |
| WOMAC c score, preop. b | 45 (15–70) | 43 (5–72) |
| Total hip (WHO), n | ||
| Normal bone density | 15 | 16 |
| Osteopenia | 9 | 9 |
| Osteoporosis | 0 | 0 |
| BMD a, g/cm² | 0.95 (0.15) | 0.99 (0.16) |
| Lumbar spine (WHO), n | ||
| Normal bone density | 13 | 12 |
| Osteopenia | 8 | 7 |
| Osteoporosis | 2 | 0 |
| BMD | 1.14 (0.21) | 1.15 (0.18) |
| Surgery, n | ||
| Cup (Pinnacle / Regenerex) | 26 / 0 | 1 / 24 |
| Articulation, mm (32 / 28) | 26 / 0 | 24 / 1 |
mean (SD).
median (range).
Western Ontario and McMaster Universities osteoarthritis index.
Skeletal bone mass measured in 49 patients at inclusion, contralateral hip.
Skeletal bone mass measured in 42 patients in whom lumbar spine could be evaluated at inclusion.
Change (mean (SD) %) in bone mineral density (BMD)
| Change in BMD | Ultra-short stem (n = 26) | Conventional stem (n = 25) | Difference (95% CI) | p-value | |
| Zone 1 | |||||
| 3 months | (n = 25/24) | −6.4 (11.9) | −13.9 (8.5) | −7.6 (−13.5 to −1.6) | |
| 6 months | (n = 25/23) | −2.8 (13.0) | −16.5 (8.6) | −13.7 (−20.2 to −7.2) | |
| 1 year | (n = 25/23) | −4.0 (15.8) | −17.9 (8.8) | −14.0 (−21.5 to −6.4) | |
| 2 years | (n = 24/23) | −2.5 (18.2) | −20.6 (9.8) | −18.2 (−26.8 to −9.5) | < 0.001 |
| Zone 7 | |||||
| 3 months | (n = 25/24) | −10.7 (9.2) | −16.3 (9.1) | −5.6 (−10.8 to −0.3) | |
| 6 months | (n = 25/23) | –11.5 (10.4) | −18.2 (11.4) | −6.7 (−13.1 to −0.4) | |
| 1 year | (n = 25/23) | −11.2 (11.8) | −19.1 (12.7) | −7.9 (−15.0 to −0.8) | |
| 2 years | (n = 24/23) | −12.8 (13.5) | −17.3 (11.3) | −4.5 (−11.8 to −2.8) | 0.4 |
| Zones 1–7 | |||||
| 3 months | (n = 25/24) | −4.0 (4.3) | −7.9 (4.8) | −3.9 (−6.5 to −1.3) | |
| 6 months | (n = 25/23) | −1.9 (5.7) | −7.7 (5.7) | −5.8 (−9.0 to −2.5) | |
| 1 year | (n = 25/23) | −1.7 (5.9) | −7.0 (5.4) | −5.3 (−8.5 to −2.0) | |
| 2 years | (n = 24/23) | –0.3 (7.8) | –5.5 (4.7) | –5.3 (–9.1 to –1.5) | 0.02 |
p-value determined with Student’s t-test.
Last observation carried forward was used twice due to missing data.
Figure 5.Mean percentage change in BMD. Error bars indicate 95% CI. Differences were analyzed with Student’s t-test. p < 0.05.
Stem migration as maximum total point motion (MTPM) measured with radiostereometry (RSA). Values are median (range) mm.
| Stem migration, MTPM (mm) | Ultra-short stem (n = 26) | Conventional stem (n = 25) | p-value | |
| 6 weeks | (n = 25/24) | 1.51 (0.33–5.44) | 0.74 (0.13–5.29) | |
| 3 months | (n = 25/24) | 1.65 (0.27–5.62) | 0.74 (0.08–7.05) | |
| 6 months | (n = 25/23) | 1.59 (0.43–5.72) | 0.54 (0.25–7.91) | |
| 1 year | (n = 25/23) | 1.59 (0.45–5.81) | 0.62 (0.20–7.73) | |
| 2 years | (n = 24/23) | 1.71 (0.39–6.00) | 0.87 (0.87–7.47) | 0.01 |
p-value determined with Mann-Whitney U-test.
Last observation carried forward was used 3 times due to missing data.
Figure 6.Stem migration as maximum total point motion (MTPM) for individual stems. Red lines correspond to ultra-short stems and green lines correspond to conventional stems. Solid black line = MTPM ultra-short stems (median). Dashed black line = MTPM conventional stems (median)
Adverse events during the study
| Adverse events | Ultra-short stem (n = 26) | Conventional stem (n = 25) | Total (n) |
| Drug-related | |||
| Bisphosphonates | 1 | 1 | |
| Glucocorticosteriods (orally) | |||
| > 1 month | 2 | 2 | |
| < 2 weeks | 2 | 1 | 3 |
| Calcium + vitamin D | 1 | 1 | 2 |
| Anti-estrogen | 1 | 1 | |
| NSAIDs | 7 | 7 | 14 |
| Surgery-related | |||
| Periprosthetic fracture | 1 | 1 | |
| Periprosthetic infection | 1 | 1 | |
| Lateral thigh pain | 2 | 4 | 6 |
| Mid-thigh pain at 6 weeks | 3 | 6 | 9 |
| at 3 months | 2 | 4 | 6 |
| at 6 months | 2 | 3 | 5 |
| Leg length discrepancy | |||
| > 10 mm | 2 | 2 | |
| Other adverse events | |||
| Low back pain | 3 | 4 | 7 |
| Pain, contralateral hip | 3 | 4 | 7 |
| THA, contralateral hip | 9 | 4 | 13 |
| Knee pain | 4 | 4 | |
| Ischialgia | 2 | 2 | |
| Skin rash/blisters | 2 | 2 | |
| Urticaria | 1 | 1 | |
| Polymyalgia rheumatica | 2 | 2 | |
| Malignancy | 1 | 2 | 3 |
| Died | 1 | 1 | 2 |
| Total (n) | 45 | 51 | 96 |